{"entity":{"id":"nct06888648","kind":"trial","name":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","aka":[],"tldr":"A phase 1/2 trial of sintilimab in pancreatic cancer, run by Zhejiang University, not yet recruiting.","summary":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer. is a phase 1/2, interventional study registered as NCT06888648 by Zhejiang University, with a registry enrolment figure of 30 participants, started 2025-04-01 and due to reach its primary completion in 2027-04-01. Interventions recorded: individualized anti-tumor new antigen iNeo-Vac-R01 injection; mFOLFIRINOX Treatment Regimen; Sintilimab injection. Conditions listed: Pancreatic Cancer Metastatic; Pancreatic Cancer Non-resectable. Primary outcome: Occurence and frequence of AE and SAE. Pancreatic eligibility wording from the registry: \"Evaluation as metastatic pancreatic cancer or postoperative recurrence according to the 2024 NCCN guidelines;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06888648","url":"https://clinicaltrials.gov/study/NCT06888648"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["sintilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06888648","phase":"1/2","setting":"Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen MRNA Therapy in Combination with PD-1 Antibody and Chemotherapy for Advanced Pancreatic Cancer.","sponsor":"Zhejiang University","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06888648/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}